Scpharmaceuticals Inc Quick Ratio (SCPH) starting from the second quarter 2025 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Scpharmaceuticals Inc   (NASDAQ: SCPH)

Scpharmaceuticals Inc 's Quick Ratio

SCPH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2025, Quick Ratio fell to 2.02 a new company low.

Within Major Pharmaceutical Preparations industry 255 other companies have achieved higher Quick Ratio than Scpharmaceuticals Inc in second quarter 2025. While Quick Ratio total ranking in the second quarter 2025 has deteriorated compared to the prior quarter from 557 to 911.

Explain Quick Ratio?
How much Cash & cash equivalents SCPH´s has?
What are SCPH´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SCPH Quick Ratio (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2
Y / Y Current Liabilities Change 58.29 % 32.34 % 12.96 % 40.46 % 100.06 %
Y / Y Cash & cash equivalent Change 5.99 % -1.54 % -0.47 % 1.43 % -62.57 %
Quick Ratio MRQ 2.02 3.58 5.17 6.09 3.02
SCPH's Total Ranking # 911 # 557 # 544 # 476 # 807
Seq. Current Liabilities Change 25.58 % 9.71 % -2.63 % 18 % 4.99 %
Seq. Cash & cash equivalent Change -29.08 % -23.94 % -17.3 % 137.6 % -34.12 %



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 256
Healthcare Sector # 439
Overall Market # 911


Quick Ratio Statistics
High Average Low
21.72 9.98 2.02
(Jun 30 2020)   (Jun 30 2025)




Financial Statements
Scpharmaceuticals Inc 's Current Liabilities $ 20 Millions Visit SCPH's Balance sheet
Scpharmaceuticals Inc 's Cash & cash equivalent $ 41 Millions Visit SCPH's Balance sheet
Source of SCPH's Sales Visit SCPH's Sales by Geography


Cumulative Scpharmaceuticals Inc 's Quick Ratio

SCPH's Quick Ratio for the trailling 12 Months

SCPH Quick Ratio

 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth 35.77 % 38.67 % 46.05 % 63.46 % 26.99 %
Y / Y Cash & cash equivalent TTM Growth 0.89 % -19.65 % -31.43 % -38.12 % -31.17 %
Quick Ratio TTM 4.03 4.5 4.84 5 5.42
Total Ranking TTM # 3028 # 3139 # 3147 # 3122 # 3071
Seq. Current Liabilities TTM Growth 12.7 % 7.19 % 3.18 % 8.92 % 15.11 %
Seq. Cash & cash equivalent TTM Growth 0.88 % -0.34 % -0.14 % 0.49 % -19.65 %

Quick ratio ranking by company, industry and sector >> Back to SCPH Financial Strength Comparisons >> Go to Compare SCPH Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2025 to $20.17 millions, cumulative Quick Ratio decreased to 4.03 below the Scpharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 406 other companies have achieved higher Quick Ratio than Scpharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 3028, from total ranking during the twelve months ending first quarter 2025 at 3139.

Explain Quick Ratio?
How much Cash & cash equivalents SCPH´s has?
What are SCPH´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 407
Healthcare Sector # 837
Within the Market # 3028


trailing twelve months Quick Ratio Statistics
High Average Low
16.57 8.99 3.92
(Sep 30 2020)   (Sep 30 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Adagene Inc   5.52 $ 64.396  Millions$ 11.664  Millions
Repare Therapeutics Inc   5.45 $ 109.472  Millions$ 20.085  Millions
Dynavax Technologies Corporation  5.44 $ 613.729  Millions$ 112.771  Millions
Sionna Therapeutics Inc   5.43 $ 40.985  Millions$ 7.550  Millions
Nucana Plc  5.43 $ 34.978  Millions$ 6.445  Millions
Immutep Limited  5.28 $ 44.307  Millions$ 8.386  Millions
Ars Pharmaceuticals Inc   5.27 $ 240.130  Millions$ 45.599  Millions
Larimar Therapeutics Inc   5.20 $ 138.524  Millions$ 26.649  Millions
Metsera Inc   5.19 $ 530.919  Millions$ 102.308  Millions
Rain Enhancement Technologies Holdco Inc   5.14 $ 15.016  Millions$ 2.920  Millions
Zenas Biopharma Inc   5.13 $ 273.279  Millions$ 53.244  Millions
Werewolf Therapeutics Inc   5.11 $ 77.596  Millions$ 15.171  Millions
Lisata Therapeutics Inc   5.09 $ 21.970  Millions$ 4.313  Millions
Pyxis Oncology Inc   5.03 $ 88.944  Millions$ 17.678  Millions
Arcus Biosciences Inc   5.02 $ 251.000  Millions$ 50.000  Millions
Universe Pharmaceuticals Inc  5.00 $ 33,592.025  Millions$ 6,723.923  Millions
Kalvista Pharmaceuticals Inc   4.99 $ 191.465  Millions$ 38.375  Millions
Vtv Therapeutics Inc   4.97 $ 25.922  Millions$ 5.216  Millions
Hepion Pharmaceuticals Inc   4.93 $ 2.924  Millions$ 0.593  Millions
Adial Pharmaceuticals Inc   4.88 $ 5.915  Millions$ 1.211  Millions
Rafael Holdings Inc  4.85 $ 52.769  Millions$ 10.877  Millions
Q32 Bio Inc   4.75 $ 54.832  Millions$ 11.534  Millions
Transcode Therapeutics Inc   4.71 $ 7.375  Millions$ 1.565  Millions
Milestone Pharmaceuticals Inc   4.68 $ 43.417  Millions$ 9.283  Millions
Mineralys Therapeutics Inc   4.59 $ 101.788  Millions$ 22.173  Millions
Enanta Pharmaceuticals Inc  4.58 $ 204.111  Millions$ 44.549  Millions
Pasithea Therapeutics Corp   4.56 $ 7.217  Millions$ 1.582  Millions
Pepgen Inc   4.56 $ 74.653  Millions$ 16.360  Millions
Tango Therapeutics Inc   4.52 $ 180.785  Millions$ 40.025  Millions
Briacell Therapeutics Corp   4.49 $ 17.866  Millions$ 3.978  Millions

Date modified: 2026-09-26T07:33:43+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.